KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2025)

Aquestive Therapeutics (AQST) has 6 years of Change in Account Payables data on record, last reported at $19.2 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 630.16% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $19.5 million, up 601.76%, while the annual FY2025 figure was $19.5 million, 601.76% up from the prior year.
  • Change in Account Payables reached $19.2 million in Q4 2025 per AQST's latest filing, up from -$1.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $19.2 million in Q4 2025 and bottomed at -$3.0 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $1.2 million, with a median of $287000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: tumbled 1047.24% in 2021, then soared 1270.33% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $2.1 million in 2021, then tumbled by 153.6% to -$1.1 million in 2022, then grew by 5.07% to -$1.1 million in 2023, then surged by 346.82% to $2.6 million in 2024, then skyrocketed by 630.16% to $19.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $19.2 million in Q4 2025, -$1.3 million in Q3 2025, and -$323000.0 in Q2 2025.